New-Onset Atrial Fibrillation May Accelerate Kidney Function Decline: Implications for Black Patients and Cardiometabolic Care

New-onset atrial fibrillation (AF) may accelerate kidney function decline, according to a study published online May 14 in JAMA Network Open.

Yuichiro Mori, M.D., from Kyoto University in Japan, and colleagues conducted a retrospective cohort study to examine the association of new-onset AF with subsequent kidney function decline in working-age adults. Participants included screening attendees aged 35 to 59 years in sinus rhythm without previous AF, cardiovascular comorbidities, or end-stage kidney disease. A total of 23,510 adults who developed new-onset AF during the annual screening interval were matched in a 1:5 ratio to 117,550 individuals who did not develop new-onset AF.

The researchers found that the annual rate of estimated glomerular filtration rate (eGFR) decline was greater in association with new-onset AF versus no AF (−1.23 versus −0.94 mL/min/1.73 m²). An increased incidence of a 30 percent or greater eGFR decline was also seen in association with new-onset AF (hazard ratio, 2.91).

“This finding suggests the importance of cardiovascular-kidney-metabolic perspectives in AF management,” the authors write. “Further investigation is needed on the cumulative impact of AF on chronic kidney disease progression and on the effectiveness of AF treatments for improving kidney outcomes.”

Two authors disclosed ties to the biopharmaceutical industry.

Why This Matters for Black Patients

Black Americans face disproportionately high rates of chronic kidney disease, hypertension, heart failure, and other cardiometabolic conditions that frequently coexist with atrial fibrillation. Although AF has historically been diagnosed less often in Black populations, evidence suggests that Black patients often experience worse outcomes once cardiovascular disease develops. 

These new findings linking new-onset atrial fibrillation to accelerated kidney decline may underscore the importance of early identification and multidisciplinary management in patients already at elevated risk for CKD progression.

The Overlap Between New-Onset Atrial Fibrillation, CKD, and Cardiometabolic Risk

The relationship between atrial fibrillation and kidney disease is likely bidirectional. Shared risk factors — including hypertension, diabetes, obesity, and vascular disease — are prevalent in many underserved populations and contribute to both conditions. Providers treating Black patients may consider closer monitoring of renal function following a new AF diagnosis, particularly when multiple cardiometabolic comorbidities are present.

Health Equity Considerations

Structural barriers, including limited access to specialty care, delayed CKD diagnosis, and persistent cardiovascular health disparities, can compound disease burden in Black communities. As evidence continues to emerge regarding the connection between AF and kidney decline, equitable screening, follow-up, and referral pathways may be important considerations for improving long-term outcomes.

Clinical Takeaways

Here’s what clinicians can do to preserve patients’ renal health:

• Consider kidney function monitoring as part of ongoing management following a new AF diagnosis.
• Assess patients for overlapping cardiometabolic risk factors that may accelerate the progression of both cardiovascular and renal disease.
• Prioritize guideline-directed management of hypertension, diabetes, and heart failure when present.
• Encourage coordinated care among primary care, cardiology, and nephrology teams for high-risk patients.
• Address barriers to access to specialty care that may contribute to delayed diagnosis and treatment.

Abstract/Full Text

Are you a healthcare professional? Register with us today!